|
1
|
Watt FM and Driskell RR: The therapeutic
potential of stem cells. Philos Trans R Soc B Biol Sci.
365:155–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alvarez CV, Garcia-Lavandeira M,
Garcia-Rendueles MER, Diaz-Rodriguez E, Garcia-Rendueles AR,
Perez-Romero S, Vila TV, Rodrigues JS, Lear PV and Bravo SB:
Defining stem cell types: Understanding the therapeutic potential
of ESCs, ASCs, and iPS cells. J Mol Endocrinol. 49:R89–R111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zakrzewski W, Dobrzyński M, Szymonowicz M
and Rybak Z: Stem cells: Past, present, and future. Stem Cell Res
Ther. 10:682019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh VK, Saini A, Kalsan M, Kumar N and
Chandra R: Describing the stem cell potency: The various methods of
functional assessment and in silico diagnostics. Front Cell Dev
Biol. 4:1342016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pittenger MF, Discher DE, Péault BM,
Phinney DG, Hare JM and Caplan AI: Mesenchymal stem cell
perspective: Cell biology to clinical progress. NPJ Regen Med.
4:222019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martin GR: Isolation of a pluripotent cell
line from early mouse embryos cultured in medium conditioned by
teratocarcinoma stem cells. Proc Natl Acad Sci USA. 78:7634–7638.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedenstein AJ, Chailakhjan RK and
Lalykina KS: The development of fibroblast colonies in monolayer
cultures of guinea-pig bone marrow and spleen cells. Cell Tissue
Kinet. 3:393–403. 1970.PubMed/NCBI
|
|
8
|
Thomson JA, Itskovitz-Eldor J, Shapiro SS,
Waknitz MA, Swiergiel JJ, Marshall VS and Jones JM: Embryonic stem
cell lines derived from human blastocysts. Science. 282:1145–1147.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haynesworth SE, Goshima J, Goldberg VM and
Caplan AI: Characterization of cells with osteogenic potential from
human marrow. Bone. 13:81–88. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McLeod C and Baylis F: Feminists on the
inalienability of human embryos. Hypatia. 21:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caulfield T and Ogbogu U: Stem cell
research, scientific freedom and the commodification concern. EMBO
Rep. 13:12–16. 2012. View Article : Google Scholar
|
|
12
|
Marway H, Johnson SL and Widdows H:
Commodification of human tissue. Handbook of Global Bioethics. ten
Have H.A.M.J and Gordijn B: Springer Netherlands; Dordrecht,
Netherlands: pp. 581–598. 2014, View Article : Google Scholar
|
|
13
|
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH
and Bang OY; STARTING collaborators, : A long-term follow-up study
of intravenous autologous mesenchymal stem cell transplantation in
patients with ischemic stroke. Stem Cells. 28:1099–1106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhasin A, Srivastava MVP, Kumaran SS,
Mohanty S, Bhatia R, Bose S, Gaikwad S, Garg A and Airan B:
Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc
Dis Extra. 1:93–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Honmou O, Houkin K, Matsunaga T, Niitsu Y,
Ishiai S, Onodera R, Waxman SG and Kocsis JD: Intravenous
administration of auto serum-expanded autologous mesenchymal stem
cells in stroke. Brain. 134((Pt 6)): 1790–1807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Connick P, Kolappan M, Crawley C, Webber
DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ,
et al: Autologous mesenchymal stem cells for the treatment of
secondary progressive multiple sclerosis: An open-label phase 2a
proof-of-concept study. Lancet Neurol. 11:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weiss DJ, Casaburi R, Flannery R,
LeRoux-Williams M and Tashkin DP: A placebo-controlled, randomized
trial of mesenchymal stem cells in COPD. Chest. 143:1590–1598.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Götherström C, Westgren M, Shaw SWS,
Aström E, Biswas A, Byers PH, Mattar CNZ, Graham GE, Taslimi J,
Ewald U, et al: Pre- and postnatal transplantation of fetal
mesenchymal stem cells in osteogenesis imperfecta: A two-center
experience. Stem Cells Transl Med. 3:255–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heldman AW, DiFede DL, Fishman JE,
Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR,
Suncion VY, McNiece IK, et al: Transendocardial mesenchymal stem
cells and mononuclear bone marrow cells for ischemic
cardiomyopathy: The TAC-HFT randomized trial. JAMA. 311:62–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karantalis V, DiFede DL, Gerstenblith G,
Pham S, Symes J, Zambrano JP, Fishman J, Pattany P, McNiece I,
Conte J, et al: Autologous mesenchymal stem cells produce
concordant improvements in regional function, tissue perfusion, and
fibrotic burden when administered to patients undergoing coronary
artery bypass grafting: The prospective randomized study of
mesenchymal stem cell therapy in patients undergoing cardiac
surgery (PROMETHEUS) trial. Circ Res. 114:1302–1310. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rushkevich YN, Kosmacheva SM, Zabrodets
GV, Ignatenko SI, Goncharova NV, Severin IN, Likhachev SA and
Potapnev MP: The use of autologous mesenchymal stem cells for cell
therapy of patients with amyotrophic lateral sclerosis in Belarus.
Bull Exp Biol Med. 159:576–581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thakkar UG, Trivedi HL, Vanikar AV and
Dave SD: Insulin-secreting adipose-derived mesenchymal stromal
cells with bone marrow-derived hematopoietic stem cells from
autologous and allogenic sources for type 1 diabetes mellitus.
Cytotherapy. 17:940–947. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vega A, Martín-Ferrero MA, Del Canto F,
Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet
M, et al: Treatment of knee osteoarthritis with allogeneic bone
marrow mesenchymal stem cells: A randomized controlled trial.
Transplantation. 99:1681–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fernández O, Izquierdo G, Fernández V,
Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo
MD, et al: Adipose-derived mesenchymal stem cells (AdMSC) for the
treatment of secondary-progressive multiple sclerosis: A triple
blinded, placebo controlled, randomized phase I/II safety and
feasibility study. PLoS One. 13:e01958912018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Musiał-Wysocka A, Kot M and Majka M: The
pros and cons of mesenchymal stem cell-based therapies. Cell
Transplant. 28:801–812. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hmadcha A, Martin-Montalvo A, Gauthier BR,
Soria B and Capilla-Gonzalez V: Therapeutic potential of
mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol.
8:432020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
da Silva Meirelles L, Chagastelles PC and
Nardi NB: Mesenchymal stem cells reside in virtually all post-natal
organs and tissues. J Cell Sci. 119((Pt 11)): 2204–2213. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Secunda R, Vennila R, Mohanashankar AM,
Rajasundari M, Jeswanth S and Surendran R: Isolation, expansion and
characterisation of mesenchymal stem cells from human bone marrow,
adipose tissue, umbilical cord blood and matrix: A comparative
study. Cytotechnology. 67:793–807. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dominici M, Le Blanc K, Mueller I,
Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A,
Prockop D and Horwitz E: Minimal criteria for defining multipotent
mesenchymal stromal cells. The international society for cellular
therapy position statement. Cytotherapy. 8:315–317. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Viswanathan S, Shi Y, Galipeau J, Krampera
M, Leblanc K, Martin I, Nolta J, Phinney DG and Sensebe L:
Mesenchymal stem versus stromal cells: International society for
cell & gene therapy (ISCT®) mesenchymal stromal cell
committee position statement on nomenclature. Cytotherapy.
21:1019–1024. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Păunescu V, Deak E, Herman D, Siska IR,
Tănasie G, Bunu C, Anghel S, Tatu CA, Oprea TI, Henschler R, et al:
In vitro differentiation of human mesenchymal stem cells to
epithelial lineage. J Cell Mol Med. 11:502–508. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Quevedo HC, Hatzistergos KE, Oskouei BN,
Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu
Q, McNiece I, et al: Allogeneic mesenchymal stem cells restore
cardiac function in chronic ischemic cardiomyopathy via trilineage
differentiating capacity. Proc Natl Acad Sci USA. 106:14022–14027.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gervois P, Struys T, Hilkens P, Bronckaers
A, Ratajczak J, Politis C, Brône B, Lambrichts I and Martens W:
Neurogenic maturation of human dental pulp stem cells following
neurosphere generation induces morphological and
electrophysiological characteristics of functional neurons. Stem
Cells Dev. 24:296–311. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mishra PJ, Mishra PJ, Humeniuk R, Medina
DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D:
Carcinoma-associated fibroblast-like differentiation of human
mesenchymal stem cells. Cancer Res. 68:4331–4339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jotzu C, Alt E, Welte G, Li J, Hennessy
BT, Devarajan E, Krishnappa S, Pinilla S, Droll L and Song YH:
Adipose tissue-derived stem cells differentiate into
carcinoma-associated fibroblast-like cells under the influence of
tumor-derived factors. Anal Cell Pathol (Amst). 33:61–79. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miyazaki Y, Oda T, Inagaki Y, Kushige H,
Saito Y, Mori N, Takayama Y, Kumagai Y, Mitsuyama T and Kida YS:
Adipose-derived mesenchymal stem cells differentiate into
heterogeneous cancer-associated fibroblasts in a stroma-rich
xenograft model. Sci Rep. 11:46902021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee MW, Ryu S, Kim DS, Lee JW, Sung KW,
Koo HH and Yoo KH: Mesenchymal stem cells in suppression or
progression of hematologic malignancy: Current status and
challenges. Leukemia. 33:597–611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang W and Chen X, Zhang S, Fang J, Chen
M, Xu Y and Chen X: Mesenchymal stem cells as a double-edged sword
in tumor growth: Focusing on MSC-derived cytokines. Cell Mol Biol
Lett. 26:32021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bellagamba BC, de Abreu BRR, Grivicich I,
Markarian CF, Chem E, Camassola M, Nardi NB and Dihl RR: Human
mesenchymal stem cells are resistant to cytotoxic and genotoxic
effects of cisplatin in vitro. Genet Mol Biol. 39:129–134. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Honczarenko M, Le Y, Swierkowski M, Ghiran
I, Glodek AM and Silberstein LE: Human bone marrow stromal cells
express a distinct set of biologically functional chemokine
receptors. Stem Cells. 24:1030–1041. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee RH, Seo MJ, Pulin AA, Gregory CA,
Ylostalo J and Prockop DJ: The CD34-like protein PODXL and
alpha6-integrin (CD49f) identify early progenitor MSCs with
increased clonogenicity and migration to infarcted heart in mice.
Blood. 113:816–826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Williams SA, Maecker HL, French DM, Liu J,
Gregg A, Silverstein LB, Cao TC, Carano RAD and Dixit VM: USP1
deubiquitinates ID proteins to preserve a mesenchymal stem cell
program in osteosarcoma. Cell. 146:918–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhuo L, Gong J, Yang R, Sheng Y, Zhou L,
Kong X and Cao K: Inhibition of proliferation and differentiation
and promotion of apoptosis by cyclin L2 in mouse embryonic
carcinoma P19 cells. Biochem Biophys Res Commun. 390:451–457. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Puchert M and Engele J: The peculiarities
of the SDF-1/CXCL12 system: In some cells, CXCR4 and CXCR7 sing
solos, in others, they sing duets. Cell Tissue Res. 355:239–253.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Janssens R, Struyf S and Proost P: The
unique structural and functional features of CXCL12. Cell Mol
Immunol. 15:299–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
De La Luz Sierra M, Yang F, Narazaki M,
Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H and Tosato G:
Differential processing of stromal-derived factor-1alpha and
stromal-derived factor-1beta explains functional diversity. Blood.
103:2452–2459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gomes AC, Hara T, Lim VY,
Herndler-Brandstetter D, Nevius E, Sugiyama T, Tani-ichi S,
Schlenner S, Richie E, Rodewald HR, et al: Hematopoietic stem cell
niches produce lineage-instructive signals to control multipotent
progenitor differentiation. Immunity. 45:1219–1231. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Reid JC, Tanasijevic B, Golubeva D, Boyd
AL, Porras DP, Collins TJ and Bhatia M: CXCL12/CXCR4 signaling
enhances human PSC-derived hematopoietic progenitor function and
overcomes early in vivo transplantation failure. Stem Cell Reports.
10:1625–1641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Binder ZA, Siu IM, Eberhart CG, Rhys CA,
Bai RY, Staedtke V, Zhang H, Smoll NR, Piantadosi S, Piccirillo SG,
et al: Podocalyxin-like protein is expressed in glioblastoma
multiforme stem-like cells and is associated with poor outcome.
PLoS One. 8:e759452013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang J, Liu F, Lee M, Wu B, Ting K, Zara
JN, Soo C, Hezaimi KA, Zou W, Chen X, et al: NF-κB inhibits
osteogenic differentiation of mesenchymal stem cells by promoting
β-catenin degradation. Proc Natl Acad Sci. 110:9469–9474. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kolosova IA, Angelini D, Fan C, Skinner J,
Cheadle C and Johns RA: Resistin-like molecule α stimulates
proliferation of mesenchymal stem cells while maintaining their
multipotency. Stem Cells Dev. 22:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chosa N and Ishisaki A: Two novel
mechanisms for maintenance of stemness in mesenchymal stem cells:
SCRG1/BST1 axis and cell-cell adhesion through N-cadherin. Jpn Dent
Sci Rev. 54:37–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sugiyama T, Kohara H, Noda M and Nagasawa
T: Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4
chemokine signaling in bone marrow stromal cell niches. Immunity.
25:977–988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gharibi B, Ghuman MS and Hughes FJ: Akt-
and Erk-mediated regulation of proliferation and differentiation
during PDGFRβ-induced MSC self-renewal. J Cell Mol Med.
16:2789–2801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takebe N, Miele L, Harris PJ, Jeong W,
Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, hedgehog, and
wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin
Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Batsali AK, Pontikoglou C, Koutroulakis D,
Pavlaki KI, Damianaki A, Mavroudi I, Alpantaki K, Kouvidi E,
Kontakis G and Papadaki HA: Differential expression of cell cycle
and WNT pathway-related genes accounts for differences in the
growth and differentiation potential of Wharton's jelly and bone
marrow-derived mesenchymal stem cells. Stem Cell Res Ther.
8:1022017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pelullo M, Zema S, Nardozza F, Checquolo
S, Screpanti I and Bellavia D: Wnt, Notch, and TGF-β pathways
impinge on Hedgehog signaling complexity: An open window on cancer.
Front Genet. 10:7112019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wagner W, Horn P, Castoldi M, Diehlmann A,
Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V and Ho
AD: Replicative senescence of mesenchymal stem cells: A continuous
and organized process. PLoS One. 3:e22132008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Halfon S, Abramov N, Grinblat B and Ginis
I: Markers distinguishing mesenchymal stem cells from fibroblasts
are downregulated with passaging. Stem Cells Dev. 20:53–66. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pérez-Campo FM and Riancho JA: Epigenetic
mechanisms regulating mesenchymal stem cell differentiation. Curr
Genomics. 16:368–383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Teven CM, Liu X, Hu N, Tang N, Kim SH,
Huang E, Yang K, Li M, Gao JL, Liu H, et al: Epigenetic regulation
of mesenchymal stem cells: A focus on osteogenic and adipogenic
differentiation. Stem Cells Int. 2011:2013712011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Srinageshwar B, Maiti P, Dunbar GL and
Rossignol J: Role of epigenetics in stem cell proliferation and
differentiation: Implications for treating neurodegenerative
diseases. Int J Mol Sci. 17:1992016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Escacena N, Quesada-Hernández E,
Capilla-Gonzalez V, Soria B and Hmadcha A: Bottlenecks in the
efficient use of advanced therapy medicinal products based on
mesenchymal stromal cells. Stem Cells Int. 2015:8957142015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang D and Kilian KA: The effect of
mesenchymal stem cell shape on the maintenance of multipotency.
Biomaterials. 34:3962–3969. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Rathbone SR, Glossop JR, Gough JE and
Cartmell SH: Cyclic tensile strain upon human mesenchymal stem
cells in 2D and 3D culture differentially influences CCNL2, WDR61
and BAHCC1 gene expression levels. J Mech Behav Biomed Mater.
11:82–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cao C, Li L, Li H, He X, Wu G and Yu X:
Cyclic biaxial tensile strain promotes bone marrow-derived
mesenchymal stem cells to differentiate into cardiomyocyte-like
cells by miRNA-27a. Int J Biochem Cell Biol. 99:125–132. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang L, Wang Y, Zhou N, Feng Y and Yang
X: Cyclic tensile stress promotes osteogenic differentiation of
adipose stem cells via ERK and p38 pathways. Stem Cell Res.
37:1014332019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lazarus HM, Haynesworth SE, Gerson SL,
Rosenthal NS and Caplan AI: Ex vivo expansion and subsequent
infusion of human bone marrow-derived stromal progenitor cells
(mesenchymal progenitor cells): Implications for therapeutic use.
Bone Marrow Transplant. 16:557–564. 1995.PubMed/NCBI
|
|
69
|
Galipeau J and Sensébé L: Mesenchymal
stromal cells: Clinical challenges and therapeutic opportunities.
Cell Stem Cell. 22:824–833. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lukomska B, Stanaszek L, Zuba-Surma E,
Legosz P, Sarzynska S and Drela K: Challenges and controversies in
human mesenchymal stem cell therapy. Stem Cells Int.
2019:96285362019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gálvez P, Clares B, Bermejo M, Hmadcha A
and Soria B: Standard requirement of a microbiological quality
control program for the manufacture of human mesenchymal stem cells
for clinical use. Stem Cells Dev. 23:1074–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Galvez-Martin P, Sabata R, Verges J,
Zugaza JL, Ruiz A and Clares B: Mesenchymal stem cells as
therapeutics agents: Quality and environmental regulatory aspects.
Stem Cells Int. 2016:97834082016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang YHK: Aging of mesenchymal stem cells:
Implication in regenerative medicine. Regen Ther. 9:120–122. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fafián-Labora JA, Morente-López M and
Arufe MC: Effect of aging on behaviour of mesenchymal stem cells.
World J Stem Cells. 11:337–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Huang XP, Sun Z, Miyagi Y, McDonald KH,
Zhang L, Weisel RD and Li RK: Differentiation of allogeneic
mesenchymal stem cells induces immunogenicity and limits their
long-term benefits for myocardial repair. Circulation.
122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Cho PS, Messina DJ, Hirsh EL, Chi N,
Goldman SN, Lo DP, Harris IR, Popma SH, Sachs DH and Huang CA:
Immunogenicity of umbilical cord tissue-derived cells. Blood.
111:430–438. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Faiella W and Atoui R: Immunotolerant
properties of mesenchymal stem cells: Updated review. Stem Cells
Int. 2016:18595672016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Dhingra S, Li P, Huang XP, Guo J, Wu J,
Mihic A, Li SH, Zang WF, Shen D, Weisel RD, et al: Preserving
prostaglandin E2 level prevents rejection of implanted allogeneic
mesenchymal stem cells and restores postinfarction ventricular
function. Circulation. 128((11 Suppl 1)): S69–S78. 2013.PubMed/NCBI
|
|
79
|
Gu Z, Tan W, Ji J, Feng G, Meng Y, Da Z,
Guo G, Xia Y, Zhu X, Shi G and Cheng C: Rapamycin reverses the
senescent phenotype and improves immunoregulation of mesenchymal
stem cells from MRL/lpr mice and systemic lupus erythematosus
patients through inhibition of the mTOR signaling pathway. Aging
(Albany NY). 8:1102–1114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ankrum JA, Ong JF and Karp JM: Mesenchymal
stem cells: Immune evasive, not immune privileged. Nat Biotechnol.
32:252–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zazzeroni L, Lanzoni G, Pasquinelli G and
Ricordi C: Considerations on the harvesting site and donor
derivation for mesenchymal stem cells-based strategies for
diabetes. CellR4 Repair Replace Regen Reprogram.
5:e24352017.PubMed/NCBI
|
|
82
|
Gao L, Bird AK, Meednu N, Dauenhauer K,
Liesveld J, Anolik J and Looney RJ: Bone marrow-derived mesenchymal
stem cells from patients with systemic lupus erythematosus have a
senescence-associated secretory phenotype mediated by a
mitochondrial antiviral signaling protein-interferon-β feedback
loop. Arthritis Rheumatol. 69:1623–1635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ji J, Wu Y, Meng Y, Zhang L, Feng G, Xia
Y, Xue W, Zhao S, Gu Z and Shao X: JAK-STAT signaling mediates the
senescence of bone marrow-mesenchymal stem cells from systemic
lupus erythematosus patients. Acta Biochim Biophys Sin (Shanghai).
49:208–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhu Y and Feng X: Genetic contribution to
mesenchymal stem cell dysfunction in systemic lupus erythematosus.
Stem Cell Res Ther. 9:1492018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen DC, Lin SZ, Fan JR, Lin CH, Lee W,
Lin CC, Liu YJ, Tsai CH, Chen JC, Cho DY, et al: Intracerebral
implantation of autologous peripheral blood stem cells in stroke
patients: A randomized phase II study. Cell Transplant.
23:1599–1612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Taguchi A, Sakai C, Soma T, Kasahara Y,
Stern DM, Kajimoto K, Ihara M, Daimon T, Yamahara K, Doi K, et al:
Intravenous autologous bone marrow mononuclear cell transplantation
for stroke: Phase1/2a clinical trial in a homogeneous group of
stroke patients. Stem Cells Dev. 24:2207–2218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hess DC, Wechsler LR, Clark WM, Savitz SI,
Ford GA, Chiu D, Yavagal DR, Uchino K, Liebeskind DS, Auchus AP, et
al: Safety and efficacy of multipotent adult progenitor cells in
acute ischaemic stroke (MASTERS): A randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet Neurol. 16:360–368. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bhatia V, Gupta V, Khurana D, Sharma RR
and Khandelwal N: Randomized assessment of the safety and efficacy
of intra-arterial infusion of autologous wtem cells in wubacute
ischemic stroke. AJNR Am J Neuroradiol. 39:899–904. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Gautam J, Alaref A, Hassan A, Kandel RS,
Mishra R and Jahan N: Safety and efficacy of stem cell therapy in
patients with ischemic stroke. Cureus. 12:e99172020.PubMed/NCBI
|
|
90
|
Trachtenberg B, Velazquez DL, Williams AR,
McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R,
Mendizabal A, et al: Rationale and design of the transendocardial
injection of autologous human cells (bone marrow or mesenchymal) in
chronic ischemic left ventricular dysfunction and heart failure
secondary to myocardial infarction (TAC-HFT) trial: A randomized,
double-blind, placebo-controlled study of safety and efficacy. Am
Heart J. 161:487–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mushtaq M, DiFede DL, Golpanian S, Khan A,
Gomes SA, Mendizabal A, Heldman AW and Hare JM: Rationale and
design of the percutaneous stem cell injection delivery effects on
neomyogenesis in dilated cardiomyopathy (The POSEIDON-DCM Study). J
Cardiovasc Transl Res. 7:769–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hare JM, DiFede DL, Rieger AC, Florea V,
Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ,
et al: Randomized comparison of allogeneic versus autologous
mesenchymal stem cells for nonischemic dilated cardiomyopathy:
POSEIDON-DCM Trial. J Am Coll Cardiol. 69:526–537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kidd S, Spaeth E, Dembinski JL, Dietrich
M, Watson K, Klopp A, Battula L, Weil M, Andreeff M and Marini FC:
Direct evidence of mesenchymal stem cell tropism for tumor and
wounding microenvironments using in vivo bioluminescence imaging.
Stem Cells. 27:2614–2623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Spaeth E, Klopp A, Dembinski J, Andreeff M
and Marini F: Inflammation and tumor microenvironments: Defining
the migratory itinerary of mesenchymal stem cells. Gene Ther.
15:730–738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kolaczkowska E and Kubes P: Neutrophil
recruitment and function in health and inflammation. Nat Rev
Immunol. 13:159–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Dimarino AM, Caplan AI and Bonfield TL:
Mesenchymal stem cells in tissue repair. Front Immunol. 4:2012013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ayala-Cuellar AP, Kang JH, Jeung EB and
Choi KC: Roles of mesenchymal stem cells in tissue regeneration and
immunomodulation. Biomol Ther (Seoul). 27:25–33. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Julier Z, Park AJ, Briquez PS and Martino
MM: Promoting tissue regeneration by modulating the immune system.
Acta Biomater. 53:13–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Prockop DJ and Oh JY: Mesenchymal
stem/stromal cells (MSCs): Role as guardians of inflammation. Mol
Ther. 20:14–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Song J, Kang HJ, Ju HM, Park A, Park H,
Hong JS, Kim CJ, Shim JY, Yu J and Choi J: Umbilical cord-derived
mesenchymal stem cell extracts ameliorate atopic dermatitis in mice
by reducing the T cell responses. Sci Rep. 9:66232019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ren G, Zhao X, Zhang L, Zhang J,
L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C and Shi Y:
Inflammatory cytokine-induced intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1 in mesenchymal stem cells are
critical for immunosuppression. J Immunol. 184:2321–2328. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li Y, Zhang D, Xu L, Dong L, Zheng J, Lin
Y, Huang J, Zhang Y, Tao Y, Zang X, et al: Cell-cell contact with
proinflammatory macrophages enhances the immunotherapeutic effect
of mesenchymal stem cells in two abortion models. Cell Mol Immunol.
16:908–920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nitzsche F, Müller C, Lukomska B,
Jolkkonen J, Deten A and Boltze J: Concise review: MSC adhesion
cascade-insights into homing and transendothelial migration. Stem
Cells. 35:1446–1460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Caplan H, Olson SD, Kumar A, George M,
Prabhakara KS, Wenzel P, Bedi S, Toledano-Furman NE, Triolo F,
Kamhieh-Milz J, et al: Mesenchymal stromal cell therapeutic
delivery: Translational challenges to clinical application. Front
Immunol. 10:16452019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ullah M, Liu DD and Thakor AS: Mesenchymal
stromal cell homing: Mechanisms and strategies for improvement.
iScience. 15:421–438. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Fiore EJ, Domínguez LM, Bayo J, García MG
and Mazzolini GD: Taking advantage of the potential of mesenchymal
stromal cells in liver regeneration: Cells and extracellular
vesicles as therapeutic strategies. World J Gastroenterol.
24:2427–2440. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Li H, Rong P, Ma X, Nie W, Chen C, Yang C,
Zhang J, Dong Q and Wang W: Paracrine effect of mesenchymal stem
cell as a novel therapeutic strategy for diabetic nephropathy. Life
Sci. 215:113–118. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu
Q and Xu J: Mesenchymal stromal cell-derived extracellular
vesicles: Regenerative and immunomodulatory effects and potential
applications in sepsis. Cell Tissue Res. 374:1–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Weiss ARR and Dahlke MH: Immunomodulation
by mesenchymal stem cells (MSCs): Mechanisms of action of living,
apoptotic, and dead MSCs. Front Immunol. 10:11912019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wobus M, List C, Dittrich T, Dhawan A,
Duryagina R, Arabanian LS, Kast K, Wimberger P, Stiehler M,
Hofbauer LC, et al: Breast carcinoma cells modulate the
chemoattractive activity of human bone marrow-derived mesenchymal
stromal cells by interfering with CXCL12. Int J Cancer. 136:44–54.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kalimuthu S, Oh JM, Gangadaran P, Zhu L,
Lee HW, Rajendran RL, Baek SH, Jeon YH, Jeong SY, Lee SW, et al: In
vivo tracking of chemokine receptor CXCR4-engineered mesenchymal
stem cell migration by optical molecular imaging. Stem Cells Int.
2017:80856372017. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ratajczak MZ, Bujko K, Mack A, Kucia M and
Ratajczak J: Cancer from the perspective of stem cells and
misappropriated tissue regeneration mechanisms. Leukemia.
32:2519–2526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Suzuki K, Sun R, Origuchi M, Kanehira M,
Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S and Saijo Y:
Mesenchymal stromal cells promote tumor growth through the
enhancement of neovascularization. Mol Med. 17:579–587. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lu L, Chen G, Yang J, Ma Z, Yang Y, Hu Y,
Lu Y, Cao Z, Wang Y and Wang X: Bone marrow mesenchymal stem cells
suppress growth and promote the apoptosis of glioma U251 cells
through downregulation of the PI3K/AKT signaling pathway. Biomed
Pharmacother. 112:1086252019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Bajetto A, Pattarozzi A, Corsaro A,
Barbieri F, Daga A, Bosio A, Gatti M, Pisaturo V, Sirito R and
Florio T: Different effects of human umbilical cord mesenchymal
stem cells on glioblastoma stem cells by direct cell interaction or
via released soluble factors. Front Cell Neurosci. 11:3122017.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zheng H, Zou W, Shen J, Xu L, Wang S, Fu
YX and Fan W: Opposite effects of coinjection and distant injection
of mesenchymal stem cells on breast tumor cell growth. Stem Cells
Transl Med. 5:1216–1228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Akimoto K, Kimura K, Nagano M, Takano S,
To'a Salazar G, Yamashita T and Ohneda O: Umbilical cord
blood-derived mesenchymal stem cells inhibit, but adipose
tissue-derived mesenchymal stem cells promote, glioblastoma
multiforme proliferation. Stem Cells Dev. 22:1370–1386. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Barcellos-de-Souza P, Comito G,
Pons-Segura C, Taddei ML, Gori V, Becherucci V, Bambi F, Margheri
F, Laurenzana A, Del Rosso M and Chiarugi P: Mesenchymal stem cells
are recruited and activated into carcinoma-associated fibroblasts
by prostate cancer microenvironment-derived TGF-β1. Stem Cells.
34:2536–2547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Hill BS, Pelagalli A, Passaro N and
Zannetti A: Tumor-educated mesenchymal stem cells promote
pro-metastatic phenotype. Oncotarget. 8:73296–73311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Tan HX, Xiao ZG, Huang T, Fang ZX, Liu Y
and Huang ZC: CXCR4/TGF-β1 mediated self-differentiation of human
mesenchymal stem cells to carcinoma-associated fibroblasts and
promoted colorectal carcinoma development. Cancer Biol Ther.
21:248–257. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Walter M, Liang S, Ghosh S, Hornsby PJ and
Li R: Interleukin 6 secreted from adipose stromal cells promotes
migration and invasion of breast cancer cells. Oncogene.
28:2745–2755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Tsai KS, Yang SH, Lei YP, Tsai CC, Chen
HW, Hsu CY, Chen LL, Wang HW, Miller SA, Chiou SH, et al:
Mesenchymal stem cells promote formation of colorectal tumors in
mice. Gastroenterology. 141:1046–1056. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhang T, Lee YW, Rui YF, Cheng TY, Jiang
XH and Li G: Bone marrow-derived mesenchymal stem cells promote
growth and angiogenesis of breast and prostate tumors. Stem Cell
Res Ther. 4:702013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
El-Haibi CP, Bell GW, Zhang J, Collmann
AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A,
et al: Critical role for lysyl oxidase in mesenchymal stem
cell-driven breast cancer malignancy. Proc Natl Acad Sci USA.
109:17460–17465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Patel SA, Meyer JR, Greco SJ, Corcoran KE,
Bryan M and Rameshwar P: Mesenchymal stem cells protect breast
cancer cells through regulatory T cells: Role of mesenchymal stem
cell-derived TGF-beta. J Immunol. 184:5885–5894. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gazdic M, Markovic BS, Jovicic N,
Misirkic-Marjanovic M, Djonov V, Jakovljevic V, Arsenijevic N,
Lukic ML and Volarevic V: Mesenchymal stem cells promote metastasis
of lung cancer cells by downregulating systemic antitumor immune
response. Stem Cells Int. 2017:62947172017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Ramasamy R, Lam EWF, Soeiro I, Tisato V,
Bonnet D and Dazzi F: Mesenchymal stem cells inhibit proliferation
and apoptosis of tumor cells: Impact on in vivo tumor growth.
Leukemia. 21:304–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
He N, Kong Y, Lei X, Liu Y, Wang J, Xu C,
Wang Y, Du L, Ji K, Wang Q, et al: MSCs inhibit tumor progression
and enhance radiosensitivity of breast cancer cells by
down-regulating Stat3 signaling pathway. Cell Death Dis.
9:10262018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yulyana Y, Ho IAW, Sia KC, Newman JP, Toh
XY, Endaya BB, Chan JKY, Gnecchi M, Huynh H, Chung AY, et al:
Paracrine factors of human fetal MSCs inhibit liver cancer growth
through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther.
23:746–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chen HL, Li JJ, Jiang F, Shi WJ and Chang
GY: MicroRNA-4461 derived from bone marrow mesenchymal stem cell
exosomes inhibits tumorigenesis by downregulating COPB2 expression
in colorectal cancer. Biosci Biotechnol Biochem. 84:338–346. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ho IAW, Toh HC, Ng WH, Teo YL, Guo CM, Hui
KM and Lam PYP: Human bone marrow-derived mesenchymal stem cells
suppress human glioma growth through inhibition of angiogenesis.
Stem Cells. 31:146–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Khalil C, Moussa M, Azar A, Tawk J,
Habbouche J, Salameh R, Ibrahim A and Alaaeddine N:
Anti-proliferative effects of mesenchymal stem cells (MSCs) derived
from multiple sources on ovarian cancer cell lines: An in-vitro
experimental study. J Ovarian Res. 12:702019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Li M, Kouzmina E, McCusker M, Rodin D,
Boutros PC, Paige CJ and Rodin G: Pro- and anti-inflammatory
cytokine associations with major depression in cancer patients.
Psychooncology. 26:2149–2156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Ahechu P, Zozaya G, Martí P,
Hernández-Lizoáin JL, Baixauli J, Unamuno X, Frühbeck G and Catalán
V: NLRP3 inflammasome: A possible link between obesity-associated
low-grade chronic inflammation and colorectal cancer development.
Front Immunol. 9:29182018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Mocellin S, Panelli MC, Wang E, Nagorsen D
and Marincola FM: The dual role of IL-10. Trends Immunol. 24:36–43.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Tanikawa T, Wilke CM, Kryczek I, Chen GY,
Kao J, Núñez G and Zou W: Interleukin-10 ablation promotes tumor
development, growth, and metastasis. Cancer Res. 72:420–429. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Nappo G, Handle F, Santer FR, McNeill RV,
Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ and Erb HHH:
The immunosuppressive cytokine interleukin-4 increases the
clonogenic potential of prostate stem-like cells by activation of
STAT6 signalling. Oncogenesis. 6:e3422017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Setrerrahmane S and Xu H: Tumor-related
iCnterleukins: Old validated targets for new anti-cancer drug
development. Mol Cancer. 16:1532017. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Saeedi P, Halabian R and Fooladi AA: A
revealing review of mesenchymal stem cells therapy, clinical
perspectives and modification strategies. Stem Cell Investig.
6:342019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bortolotti F, Ukovich L, Razban V,
Martinelli V, Ruozi G, Pelos B, Dore F, Giacca M and Zacchigna S:
In vivo therapeutic potential of mesenchymal stromal cells depends
on the source and the isolation procedure. Stem Cell Rep.
4:332–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Fathi E, Sanaat Z and Farahzadi R:
Mesenchymal stem cells in acute myeloid leukemia: A focus on
mechanisms involved and therapeutic concepts. Blood Res.
54:165–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Chen Y, He Y, Wang X, Lu F and Gao J:
Adipose-derived mesenchymal stem cells exhibit tumor tropism and
promote tumorsphere formation of breast cancer cells. Oncol Rep.
41:2126–2136. 2019.PubMed/NCBI
|
|
146
|
Dührsen L, Hartfuß S, Hirsch D, Geiger S,
Maire CL, Sedlacik J, Guenther C, Westphal M, Lamszus K, Hermann FG
and Schmidt NO: Preclinical analysis of human mesenchymal stem
cells: Tumor tropism and therapeutic efficiency of local HSV-TK
suicide gene therapy in glioblastoma. Oncotarget. 10:6049–6061.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Dissanayake S, Denny WA, Gamage S and
Sarojini V: Recent developments in anticancer drug delivery using
cell penetrating and tumor targeting peptides. J Control Release.
250:62–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Lagoa R, Silva J, Rodrigues JR and
Bishayee A: Advances in phytochemical delivery systems for improved
anticancer activity. Biotechnol Adv. 38:1073822020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
150
|
Ahn JO, Lee HW, Seo KW, Kang SK, Ra JC and
Youn HY: Anti-tumor effect of adipose tissue derived-mesenchymal
stem cells expressing interferon-β and treatment with cisplatin in
a xenograft mouse model for canine melanoma. PLoS One.
8:e748972013. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Shen CJ, Chan TF, Chen CC, Hsu YC, Long CY
and Lai CS: Human umbilical cord matrix-derived stem cells
expressing interferon-β gene inhibit breast cancer cells via
apoptosis. Oncotarget. 7:34172–34179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yuan ZQ, Kolluri KK, Sage EK, Gowers KHC
and Janes SM: Mesenchymal stromal cell delivery of full-length
tumor necrosis factor-related apoptosis-inducing ligand is superior
to soluble type for cancer therapy. Cytotherapy. 17:885–896. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Marini I, Siegemund M, Hutt M, Kontermann
RE and Pfizenmaier K: Antitumor activity of a mesenchymal stem cell
line stably secreting a tumor-targeted TNF-related
apoptosis-inducing ligand fusion protein. Front Immunol. 8:5362017.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Guiho R, Biteau K, Grisendi G, Chatelais
M, Brion R, Taurelle J, Renault S, Heymann D, Dominici M and Redini
F: In vitro and in vivo discrepancy in inducing apoptosis by
mesenchymal stromal cells delivering membrane-bound tumor necrosis
factor-related apoptosis inducing ligand in osteosarcoma
pre-clinical models. Cytotherapy. 20:1037–1045. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Shamili FH, Bayegi HR, Salmasi Z, Sadri K,
Mahmoudi M, Kalantari M, Ramezani M and Abnous K: Exosomes derived
from TRAIL-engineered mesenchymal stem cells with effective
anti-tumor activity in a mouse melanoma model. Int J Pharm.
549:218–229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Yang X, Du J, Xu X, Xu C and Song W:
IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in
vivo via the TRAIL pathway. J Immunol Res. 2014:e3180982014.
View Article : Google Scholar
|
|
157
|
You Q, Yao Y, Zhang Y, Fu S, Du M and
Zhang G: Effect of targeted ovarian cancer therapy using amniotic
fluid mesenchymal stem cells transfected with enhanced green
fluorescent protein-human interleukin-2 in vivo. Mol Med
Rep. 12:4859–4866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhao W, Cheng J, Shi P and Huang J: Human
umbilical cord mesenchymal stem cells with adenovirus-mediated
interleukin 12 gene transduction inhibits the growth of ovarian
carcinoma cells both in vitro and in vivo. Nan Fang Yi Ke Da Xue
Xue Bao. 31:903–907. 2011.(In Chinese). PubMed/NCBI
|
|
159
|
Zhang X, Zhang L, Xu W, Qian H, Ye S, Zhu
W, Cao H, Yan Y, Li W, Wang M, et al: Experimental therapy for lung
cancer: Umbilical cord-derived mesenchymal stem cell-mediated
interleukin-24 delivery. Curr Cancer Drug Targets. 13:92–102. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Nowakowski A, Walczak P, Lukomska B and
Janowski M: Genetic engineering of mesenchymal stem cells to induce
their migration and survival. Stem Cells Int. 2016:e49560632016.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Wei W, Huang Y, Li D, Gou HF and Wang W:
Improved therapeutic potential of MSCs by genetic modification.
Gene Ther. 25:538–547. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ocansey DKW, Pei B, Yan Y, Qian H, Zhang
X, Xu W and Mao F: Improved therapeutics of modified mesenchymal
stem cells: An update. J Transl Med. 18:422020. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Phillips MI and Tang YL: Genetic
modification of stem cells for transplantation. Adv Drug Deliv Rev.
60:160–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Bobis-Wozowicz S, Miekus K, Wybieralska E,
Jarocha D, Zawisz A, Madeja Z and Majka M: Genetically modified
adipose tissue-derived mesenchymal stem cells overexpressing CXCR4
display increased motility, invasiveness, and homing to bone marrow
of NOD/SCID mice. Exp Hematol. 39:686–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Pelagalli A, Nardelli A, Lucarelli E,
Zannetti A and Brunetti A: Autocrine signals increase ovine
mesenchymal stem cells migration through Aquaporin-1 and CXCR4
overexpression. J Cell Physiol. 233:6241–6249. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Song SW, Chang W, Song BW, Song H, Lim S,
Kim HJ, Cha MJ, Choi E, Im SH, Chang BC, et al: Integrin-linked
kinase is required in hypoxic mesenchymal stem cells for
strengthening cell adhesion to ischemic myocardium. Stem Cells.
27:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Fan YX, Gu CH, Zhang YL, Zhong BS, Wang
LZ, Zhou ZR, Wang ZY, Jia RX and Wang F: Oct4 and Sox2
overexpression improves the proliferation and differentiation of
bone mesenchymal stem cells in Xiaomeishan porcine. Genet Mol Res.
12:6067–6079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Han SM, Han SH, Coh YR, Jang G, Ra JC,
Kang SK, Lee HW and Youn HY: Enhanced proliferation and
differentiation of Oct4- and Sox2-overexpressing human adipose
tissue mesenchymal stem cells. Exp Mol Med. 46:e1012014. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Becker AD and Riet IV: Homing and
migration of mesenchymal stromal cells: How to improve the efficacy
of cell therapy? World J Stem Cells. 8:73–87. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
DelaRosa O, Dalemans W and Lombardo E:
Toll-like receptors as modulators of mesenchymal stem cells. Front
Immunol. 3:1822012. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Najar M, Krayem M, Meuleman N, Bron D and
Lagneaux L: Mesenchymal stromal cells and toll-like receptor
priming: A critical review. Immune Netw. 17:89–102. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Mekhemar MK, Dörfer CE and El-Sayed KMF:
Toll-like receptors: The key of immunotherapy in MSCs.
Immunoregulatory aspects of immunotherapy. IntechOpen; pp.
1732018
|
|
173
|
Waterman RS, Tomchuck SL, Henkle SL and
Betancourt AM: A new mesenchymal stem cell (MSC) paradigm:
Polarization into a pro-inflammatory MSC1 or an immunosuppressive
MSC2 phenotype. PLoS One. 5:e100882010. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Kim J and Hematti P: Mesenchymal stem
cell-educated macrophages: A novel type of alternatively activated
macrophages. Exp Hematol. 37:1445–1453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Cassatella MA, Mosna F, Micheletti A, Lisi
V, Tamassia N, Cont C, Calzetti F, Pelletier M, Pizzolo G and
Krampera M: Toll-like receptor-3-activated human mesenchymal
stromal cells significantly prolong the survival and function of
neutrophils. Stem Cells. 29:1001–1011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Hall SRR, Tsoyi K, Ith B, Padera RF Jr,
Lederer JA, Wang Z, Liu X and Perrella MA: Mesenchymal stromal
cells improve survival during sepsis in the absence of heme
oxygenase-1: The importance of neutrophils. Stem Cells. 31:397–407.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Jiang W and Xu J: Immune modulation by
mesenchymal stem cells. Cell Prolif. 53:e127122019.PubMed/NCBI
|
|
178
|
Kudlik G, Hegyi B, Czibula Á, Monostori É,
Buday L and Uher F: Mesenchymal stem cells promote macrophage
polarization toward M2b-like cells. Exp Cell Res. 348:36–45. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Spaggiari GM, Capobianco A, Abdelrazik H,
Becchetti F, Mingari MC and Moretta L: Mesenchymal stem cells
inhibit natural killer-cell proliferation, cytotoxicity, and
cytokine production: Role of indoleamine 2,3-dioxygenase and
prostaglandin E2. Blood. 111:1327–1333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Gonzalez H, Hagerling C and Werb Z: Roles
of the immune system in cancer: From tumor initiation to metastatic
progression. Genes Dev. 32:1267–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35 (Suppl):S185–S198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Du W, Seah I, Bougazzoul O, Choi G, Meeth
K, Bosenberg MW, Wakimoto H, Fisher D and Shah K: Stem
cell-released oncolytic herpes simplex virus has therapeutic
efficacy in brain metastatic melanomas. Proc Natl Acad Sci USA.
114:E6157–E6165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Guo Y, Zhang Z, Xu X, Xu Z, Wang S, Huang
D, Li Y, Mou X, Liu F and Xiang C: Menstrual blood-derived stem
cells as delivery vehicles for oncolytic adenovirus virotherapy for
colorectal cancer. Stem Cells Dev. 28:882–896. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Mahasa KJ, Pillis Ld, Ouifki R, Eladdadi
A, Maini P, Yoon AR and Yun CO: Mesenchymal stem cells used as
carrier cells of oncolytic adenovirus results in enhanced oncolytic
virotherapy. Sci Rep. 10:4252020. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Pessina A, Coccè V, Pascucci L, Bonomi A,
Cavicchini L, Sisto F, Ferrari M, Ciusani E, Crovace A, Falchetti
ML, et al: Mesenchymal stromal cells primed with paclitaxel attract
and kill leukaemia cells, inhibit angiogenesis and improve survival
of leukaemia-bearing mice. Br J Haematol. 160:766–778. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Gilazieva Z, Tazetdinova L, Arkhipova S,
Solovyeva V and Rizvanov A: Effect of cisplatin on ultrastructure
and viability of adipose-derived mesenchymal stem cells.
BioNanoScience. 6:534–539. 2016. View Article : Google Scholar
|
|
187
|
Nicolay NH, Perez RL, Rühle A, Trinh T,
Sisombath S, Weber KJ, Ho AD, Debus J, Saffrich R and Huber PE:
Mesenchymal stem cells maintain their defining stem cell
characteristics after treatment with cisplatin. Sci Rep.
6:200352016. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Pascucci L, Coccè V, Bonomi A, Ami D,
Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM,
et al: Paclitaxel is incorporated by mesenchymal stromal cells and
released in exosomes that inhibit in vitro tumor growth: A new
approach for drug delivery. J Control Release. 192:262–270. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Pessina A, Bonomi A, Coccè V, Invernici G,
Navone S, Cavicchini L, Sisto F, Ferrari M, Viganò L, Locatelli A,
et al: Mesenchymal stromal cells primed with paclitaxel provide a
new approach for cancer therapy. PLoS One. 6:e283212011. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Bonomi A, Coccè V, Cavicchini L, Sisto F,
Dossena M, Balzarini P, Portolani N, Ciusani E, Parati E,
Alessandri G and Pessina A: Adipose tissue-derived stromal cells
primed in vitro with paclitaxel acquire anti-tumor activity. Int J
Immunopathol Pharmacol. 26 (Suppl 1):S33–S41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Coccè V, Franzè S, Brini AT, Giannì AB,
Pascucci L, Ciusani E, Alessandri G, Farronato G, Cavicchini L,
Sordi V, et al: In vitro anticancer activity of extracellular
vesicles (EVs) secreted by gingival mesenchymal stromal cells
primed with paclitaxel. Pharmaceutics. 11:612019. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Coccè V, Farronato D, Brini AT, Masia C,
Giannì AB, Piovani G, Sisto F, Alessandri G, Angiero F and Pessina
A: Drug loaded gingival mesenchymal stromal cells (GinPa-MSCs)
inhibit in vitro proliferation of oral squamous cell carcinoma. Sci
Rep. 7:93762017. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Layek B, Sadhukha T, Panyam J and Prabha
S: Nano-engineered mesenchymal stem cells increase therapeutic
efficacy of anticancer drug through true active tumor targeting.
Mol Cancer Ther. 17:1196–1206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Moku G, Layek B, Trautman L, Putnam S,
Panyam J and Prabha S: Improving payload capacity and anti-tumor
efficacy of mesenchymal stem cells using TAT peptide functionalized
polymeric nanoparticles. Cancers (Basel). 11:4912019. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Altun İ and Sonkaya A: The most common
side effects experienced by patients were receiving first cycle of
chemotherapy. Iran J Public Health. 47:1218–1219. 2018.PubMed/NCBI
|
|
196
|
Kim W, Lee SK, Kwon YW, Chung SG and Kim
S: Pioglitazone-primed mesenchymal stem cells stimulate cell
proliferation, collagen synthesis and matrix gene expression in
tenocytes. Int J Mol Sci. 20:4722019. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Hong Y, Kim YS, Hong SH and Oh YM:
Therapeutic effects of adipose-derived stem cells pretreated with
pioglitazone in an emphysema mouse model. Exp Mol Med. 48:e2662016.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Park JS, Kim HK, Kang EY, Cho R and Oh YM:
Potential therapeutic strategy in chronic obstructive pulmonary
disease using pioglitazone-augmented Wharton's jelly-derived
mesenchymal stem cells. Tuberc Respir Dis (Seoul). 82:158–165.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Khoo BY, Nadarajan K, Shim SY, Miswan N,
Zang CB, Possinger K and Elstner E: Pretreatment of BMSCs with TZD
solution decreases the proliferation rate of MCF-7 cells by
reducing FGF4 protein expression. Mol Med Rep. 13:3406–3414. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Tsubaki M, Takeda T, Tomonari Y, Kawashima
K, Itoh T, Imano M, Satou T and Nishida S: Pioglitazone inhibits
cancer cell growth through STAT3 inhibition and enhanced AIF
expression via a PPARγ-independent pathway. J Cell Physiol.
233:3638–3647. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Moghareabed R, Hemati S, Akhavan A, Emami
H, Farghadani M, Roayaei M, Tavajoh S and Feizi A: Randomized phase
II clinical trial of pioglitazone plus chemotherapy versus
chemotherapy alone in patients with metastatic breast cancer. J
Glob Oncol. 5:832019. View Article : Google Scholar
|
|
202
|
Esmaeili S, Safaroghli-Azar A,
Pourbagheri-Sigaroodi A, Salari S, Gharehbaghian A, Hamidpour M and
Bashash D: Activation of PPARγ intensified the effects of arsenic
trioxide in acute promyelocytic leukemia through the suppression of
PI3K/Akt pathway: Proposing a novel anticancer effect for
pioglitazone. Int J Biochem Cell Biol. 122:1057392020. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Shinmura D, Togashi I, Miyoshi S,
Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Tsukada Y, Ogawa
S and Umezawa A: Pretreatment of human mesenchymal stem cells with
pioglitazone improved efficiency of cardiomyogenic
transdifferentiation and cardiac function. Stem Cells. 29:357–366.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Wang M, Cai J, Huang F, Zhu M, Zhang Q,
Yang T, Zhang X, Qian H and Xu W: Pre-treatment of human umbilical
cord-derived mesenchymal stem cells with interleukin-6 abolishes
their growth-promoting effect on gastric cancer cells. Int J Mol
Med. 35:367–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
von Bahr L, Sundberg B, Lönnies L, Sander
B, Karbach H, Hägglund H, Ljungman P, Gustafsson B, Karlsson H,
Blanc KL and Ringdén O: Long-term complications, immunologic
effects, and role of passage for outcome in mesenchymal stromal
cell therapy. Biol Blood Marrow Transplant. 18:557–564. 2012.
View Article : Google Scholar : PubMed/NCBI
|
